Adam Levy
Head of Investor Relations
Alaunos Therapeutics, Inc. (TCRT)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2021-08-30–present
-
Current
-
Current
-
Current
-
Start not stated–2026-08-21
-
Start not stated–2026-08-21
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Head of Investor Relations
2021-08-30–present
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Nexgel, Inc. (NXGL) | Chief Executive Officer and President | $373,077 | $877,177 |
| 2025 | Mineralys Therapeutics, Inc. (MLYS) | Chief Financial Officer and Secretary | $532,000 | $2,203,096 |
| 2024 | Nexgel, Inc. (NXGL) | Chief Executive Officer | $325,000 | $437,550 |
| 2024 | Mineralys Therapeutics, Inc. (MLYS) | Chief Financial Officer and Secretary | $500,000 | $2,849,200 |
| 2023 | Nexgel, Inc. (NXGL) | Chief Executive Officer | $325,000 | $442,100 |
| 2023 | Mineralys Therapeutics, Inc. (MLYS) | Chief Financial Officer and Secretary | $450,000 | $2,176,181 |
| 2022 | Nexgel, Inc. (NXGL) | Chief Executive Officer | $300,000 | $450,104 |
| 2022 | Mineralys Therapeutics, Inc. (MLYS) | Chief Financial Officer and Secretary | $334,926 | $1,016,588 |
| 2021 | Nexgel, Inc. (NXGL) | Chief Executive Officer | $180,000 | $306,482 |
| 2020 | Nexgel, Inc. (NXGL) | Chief Executive Officer | $143,077 | $226,077 |
Recent activity
Earnings-call appearances and filed executive appointments or departures, newest first.